Healthcare Royalty HCRX 深 沪
等待开盘 04-03 09:30:00 美东时间
0.00
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 总市值 0
- 52周最高 0.00
- 市盈率 静 0.00
- 换手率 0.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 2.15亿
- 历史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 0.00
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-ADC Therapeutics Announces Amended Healthcare Royalty Financing Agreement
BRIEF-ADC Therapeutics Announces Amended Healthcare Royalty Financing Agreement Feb 23 (Reuters) - ADC Therapeutics SA ADCT.N : ADC THERAPEUTICS ANNOUNCES AMENDED HEALTHCARE ROYALTY FINANCING AGREEMENT ADC THERAPEUTICS SA - AGREEMENT REDUCES CHANGE OF CONTROL PAYMENT TO $150 MILLION THROUGH 2027 ADC
02-23 20:28
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
Nanobiotix reported key milestones in its third quarter 2025 update, including a $71 million non-dilutive royalty financing with HCRx, advancement of JNJ-1900 (NBTXR3) clinical development with esophageal cancer data and Phase 3 study transfer to J&J, and progress in the Curadigm Nanoprimer program. The company expects JNJ-1900 clinical updates in 2026 across melanoma, lung, pancreatic, and esophageal cancers. With €20.4 million in cash and the H...
2025-11-24 21:15
UPDATE 3-KKR’s profit beats forecast on credit-led inflows, one-off charge weighs
Q3 inflows of $43 billion Shares rise, then fall on news of Asia charge KKR earns rising fees for managing assets Updates share movement paragraphs 3-4 By Isla Binnie and Arasu Kannagi Basil Nov 7 (Re...
2025-11-07 20:02
KKR's quarterly profit beats estimates on rising inflows
By Isla Binnie Nov 7 (Reuters) - KKR KKR.N reported a rise in third-quarter profit that beat Wall Street's expectations on Friday, boosted by strong fundraising, particularly in its insurance unit and...
2025-11-07 19:51
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Nanobiotix has entered into a $71 million royalty-based financing agreement with HealthCare Royalty to extend its cash runway into early 2028. The funding supports development in head and neck cancer and lung cancer, and enables self-sustainability and growth of next-generation nanotherapeutic platforms. HealthCare Royalty will receive a capped portion of milestones and royalties on JNJ-1900 (NBTXR3). The upfront payment is $50 million, with an a...
2025-10-31 07:00
BRIEF-Clearside Biomedical - On Sept 4, Enters Amendment Agreement With Healthcare Royalty Partners - SEC Filing
Sept 8 (Reuters) - Clearside Biomedical Inc CLSD.O: CLEARSIDE BIOMEDICAL INC - ON SEPT 4, ENTERS AMENDMENT AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS - SEC FILING CLEARSIDE BIOMEDICAL INC - SELLER REC...
2025-09-08 19:53
Clearside Biomedical Secures $3 Million Agreement for SCS Microinjector Assets with Healthcare Royalty Partners
Clearside Biomedical Inc. has announced a significant update to its material agreements by entering an Omnibus Amendment Agreement with Clearside Royalty LLC, Healthcare Royalty Partners IV, L.P., and...
2025-09-08 19:17
BRIEF-KKR Is Set To Acquire A Majority Stake In Healthcare Royalty Partners- WSJ
July 30 (Reuters) - KKR IS SET TO ACQUIRE A MAJORITY STAKE IN HEALTHCARE ROYALTY PARTNERS- WSJ Source: https://tinyurl.com/32xfbv9c ((Reuters.Briefs@thomsonreuters.com;))
2025-07-30 20:05
BRIEF-Liquidia Receives $50 Million From Healthcare Royalty Following First Commercial Sale Of YUTREPIA
June 23 (Reuters) - Liquidia Corp LQDA.O: LIQUIDIA RECEIVES $50 MILLION FROM HEALTHCARE ROYALTY (HCRX) FOLLOWING FIRST COMMERCIAL SALE OF YUTREPIA™ LIQUIDIA CORP - UNDER TERMS OF HCR AGREEMENT, RECEIV...
2025-06-24 05:02
